| Labcorp

Adam H. Schechter

Chairman, President and Chief Executive Officer

Adam Schechter became chief executive officer of Labcorp (NYSE: LH) in November 2019 and chairman in May 2020. Previously, Schechter was named lead independent director in January 2019 after serving on the board since 2013.

Under Schechter’s leadership, Labcorp, a leading global life sciences company with more than 80,000 employees, harnesses science, innovation and technology to improve health and improve lives. Through its strong diagnostics and drug development capabilities, vast health data and insights, and extensive global laboratory network, the company advances healthcare across all major clinical and therapeutic areas, including oncology, Alzheimer’s, autoimmune and liver diseases, and more.

Labcorp is helping customers bring innovative, life-changing treatments and vaccines to market by leveraging its combined expertise in drug development and diagnostics. With these capabilities, Schechter, with his colleagues at Labcorp, created a model for addressing emerging health crises with their response to the COVID-19 pandemic and the Monkeypox virus.

Schechter joined Labcorp after a long and distinguished career at Merck, where he served as executive vice president and president of global human health and was a member of the executive committee. At Merck, among other accomplishments, Schechter focused on ensuring that Merck’s medicines and vaccines were available to people around the world, led a large global organization across the spectrum of commercial operations, transformed Merck’s commercial model, and led the integration of Merck and Schering-Plough.

He is the vice chair of the Board of Directors for the American Clinical Laboratory Association (ACLA), a board member for Water.org, and serves as an independent director on the board of DaVita, Inc. Schechter is chair of the Corporate Advisory Council for the National Alliance for Hispanic Health, a longtime leader and advocate on Hispanic issues and an Executive Advisor to its Healthy Americas Foundation.

Schechter holds a Bachelor of Arts in Biology from La Salle University and was awarded an honorary Doctor of Humane Letters degree from the university in 2021.

Peter M. Neupert

Member of the Nominating and Corporate Governance Committee

Peter M. Neupert

Director

Peter M. Neupert has served as a director of the Company since January 1, 2013. Mr. Neupert was an Operating Partner at Health Evolution Partners, a health only, middle market private equity firm, from January 2012 until June 2015. Prior to that, Mr. Neupert served as Corporate Vice President of the Microsoft Health Solutions Group from its formation in 2005 to January 2012. Mr. Neupert served on the President’s Information Technology Advisory Committee (PITAC), co-chairing the Health Information Technology Subcommittee and helping to drive the “Revolutionizing Health Care Through Information Technology” report, published in June 2004. Mr. Neupert served as the founding President and Chief Executive Officer of drugstore.com from 1998 to 2001 and as Chairman of the board of directors through September 2004. Mr. Neupert has served as a director of Fortrea Holdings, Inc. since it became publicly traded in June 2023. Mr. Neupert has served as a director of Adaptive Biotechnologies Corporation since December 2013 and currently serves as the Lead Independent Director. He served on the Board of Directors of Quality Systems, Inc., now known as NextGen Healthcare, Inc., from August 2013 to January 2014. He previously served as a trustee for the Fred Hutchinson Cancer Research Center and was an active member of the Institute of Medicine’s Roundtable on Value & Science-Driven Healthcare from 2007 to 2011. Mr. Neupert brings to the Board experience as a recognized expert in health information technology and perspective on how to grow shareholder value leveraging business strategies with technology. Mr. Neupert is an audit committee financial expert as a result of his experience, including his experience as CEO and Chairman of drugstore.com. Mr. Neupert previously served as the Board’s lead independent director from July 2019 until June 2023.

Financial Expert

Garheng Kong M.D., Ph.D.

Lead Independent Director, Chair of the Nominating and Corporate Governance

Garheng Kong has served as a director of the Company since December 1, 2013 and Lead Independent Director since June 2023. Dr. Kong also serves as the Chair of the Nominating and Corporate Governance Committee for the Company. Dr. Kong is the managing partner of HealthQuest Capital, a healthcare-focused investment firm, a role he has held since he founded HealthQuest Capital in 2012. He was previously a general partner at Sofinnova Capital, a position he held from 2010 to 2013. Before joining Sofinnova, Dr. Kong was a general partner from 2000 to 2010 at Intersouth Partners, a venture capital firm where he was a founding investor or board member for various life science ventures, several of which were acquired by large pharmaceutical companies. Prior to his investing career, Dr. Kong was employed by GlaxoSmithKline, McKinsey & Company, and TherOx. Dr. Kong has served on the board of directors of Venus Concept Inc., a medical technology company, since June 2017, when HealthQuest made an investment in Venus Concept and also currently serves on the board of directors of Xeris Pharmaceuticals, a biopharma company (formerly Strongbridge Biopharma plc, where Dr. Kong served on the board of directors since 2015). Dr. Kong previously served on the board of directors of Alimera Sciences, Inc., a pharmaceutical company that specializes in the commercialization and development of ophthalmic pharmaceuticals, from October 2012 to May 2023 and of Histogenics Corporation, a public biotechnology company, from July 2012 until February 2019, each of which he joined in connection with an investment by Sofinnova, and Avedro, Inc., a commercial-stage ophthalmic medical technology company, from April 2017 until November 2019. Dr. Kong also previously served on the Board of Melinta Therapeutics, a pharmaceutical company formerly known as Cempra Pharmaceuticals, from September 2006 until June 2019. Dr. Kong also sits on the boards of Duke University Medical Center, Be The Match, Dell Children’s Foundation, UT President’s Commercial Advisory Board, and the Austin Healthcare Council. Dr. Kong received undergraduate degrees in both Chemical Engineering and Biological Sciences from Stanford, and earned an M.D., Ph.D. and MBA from Duke University.

Lead Director

D. Gary Gilliland M.D., Ph.D.

Director

D. Gary Gilliland has served as a director of the Company since April 1, 2014. Dr. Gilliland has served as President and Director Emeritus of the Fred Hutchinson Cancer Research Center, a research organization, in Seattle, WA since January 31, 2020. From January 2, 2015 to January 30, 2020, Dr. Gilliland previously served as President and Director of the Fred Hutchinson Cancer Research Center. Prior to that, he was the inaugural Vice Dean and Vice President for Precision Medicine at the University of Pennsylvania Perelman School of Medicine from October 2013 to January 2015, where he was responsible for synthesizing research and clinical-care initiatives across all medical disciplines including cancer, heart and vascular medicine, neurosciences, genetics, and pathology, to create a national model for the delivery of precise, personalized medicine. From 2009 until he joined Penn Medicine in 2013, Dr. Gilliland was Senior Vice President of Merck Research Laboratories and Oncology Franchise Head. At Merck, Dr. Gilliland oversaw first-in-human studies, proof-of-concept trials, and Phase II/III registration trials that included the development of pembrolizumab (anti-PD1) for treatment of cancer, and managed all preclinical and clinical oncology-licensing activities. Prior to joining Merck, Dr. Gilliland was a member of the faculty at Harvard Medical School for nearly 20 years, where he served as Professor of Medicine and a Professor of Stem Cell and Regenerative Biology. He was also an Investigator of the Howard Hughes Medical Institute from 1996 to 2009, Director of the Leukemia Program at the Dana-Farber/Harvard Cancer Center from 2002 to 2009, and Director of the Cancer Stem Cell Program of the Harvard Stem Cell Institute from 2004 to 2009. Dr. Gilliland has a Ph.D. in Microbiology from UCLA and an M.D. from UCSF. He is board-certified in Internal Medicine and had his Fellowship training in Hematology and Oncology, each at Harvard Medical School. He is a Fellow of the American Association for Cancer Research (AACR), and is an elected member of the American Society of Clinical Investigation (ASCI), the Association of American Physicians (AAP), the American Academy of Arts of Sciences (AAAS) and the National Academy of Medicine (NAM).

Kerrii B. Anderson

Director

Kerrii B. Anderson has served as a director of the Company since May 17, 2006. Ms. Anderson is the former Chief Executive Officer, President and Chief Financial Officer of Wendy’s International. Prior to joining Wendy’s in 2000, she was senior vice president and chief financial officer for 14 years for M/I Schottenstein Homes, Inc., a NYSE company that builds single-family homes.

Ms. Anderson has served as a director of Abercrombie & Fitch Co. since February 2018, The Sherwin-Williams Company since April 2019, and Worthington Industries, Inc. since September 2010. She was previously a director of the board of Chiquita Brands International from 2009 to 2012, and was chairwoman of the board from 2012 until the company’s acquisition in 2015. She was also a member of the board of P.F. Chang’s China Bistro from 2009 to 2012. Ms. Anderson also serves on the boards of the following non-profit entities: The Columbus Foundation and Elon University Board of Trustees.

Ms. Anderson has a strong record of leadership in operations, strategy, finance and talent management as a result of her experience at Wendy’s. Ms. Anderson also has significant expertise in the areas of accounting and financial reporting, corporate finance, corporate governance, and executive compensation through her service on other large public company boards. The breadth of experience enables Ms. Anderson to advise our Board on a variety of matters related to global operations and business strategy.

Financial Expert